Silence Therapeutics (SLN) to Release Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is projected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 8:00 AM ET.

Silence Therapeutics Trading Up 5.8%

SLN opened at $5.33 on Wednesday. The stock has a fifty day moving average price of $5.42 and a 200 day moving average price of $5.75. Silence Therapeutics has a 1 year low of $1.97 and a 1 year high of $7.78. The stock has a market cap of $251.76 million, a price-to-earnings ratio of -3.95 and a beta of 1.35.

Institutional Investors Weigh In On Silence Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SLN. XTX Topco Ltd bought a new position in shares of Silence Therapeutics in the fourth quarter worth about $71,000. Quadrature Capital Ltd acquired a new stake in Silence Therapeutics in the 4th quarter valued at approximately $331,000. Opaleye Management Inc. bought a new position in Silence Therapeutics in the 4th quarter worth approximately $480,000. Millennium Management LLC lifted its holdings in shares of Silence Therapeutics by 121.0% during the fourth quarter. Millennium Management LLC now owns 659,592 shares of the company’s stock worth $4,010,000 after buying an additional 361,080 shares during the last quarter. Finally, ADAR1 Capital Management LLC boosted its position in shares of Silence Therapeutics by 26.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock valued at $144,000 after acquiring an additional 5,000 shares during the period. 98.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Silence Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. Four analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $32.60.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.